Head to Head Survey: Advanced Accelerator Application (AAAP) vs. DARA Biosciences (DARA)
Advanced Accelerator Application (NASDAQ: AAAP) and DARA Biosciences (NASDAQ:DARA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.
Volatility & Risk
Advanced Accelerator Application has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, DARA Biosciences has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
This table compares Advanced Accelerator Application and DARA Biosciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Advanced Accelerator Application||$121.01 million||29.56||-$27.99 million||($1.31)||-62.09|
DARA Biosciences has lower revenue, but higher earnings than Advanced Accelerator Application. Advanced Accelerator Application is trading at a lower price-to-earnings ratio than DARA Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
39.1% of Advanced Accelerator Application shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Advanced Accelerator Application and DARA Biosciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Advanced Accelerator Application||0||2||2||0||2.50|
Advanced Accelerator Application currently has a consensus target price of $64.50, indicating a potential downside of 20.70%. Given Advanced Accelerator Application’s higher possible upside, equities research analysts clearly believe Advanced Accelerator Application is more favorable than DARA Biosciences.
This table compares Advanced Accelerator Application and DARA Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Advanced Accelerator Application||-43.93%||-20.59%||-14.58%|
Advanced Accelerator Application beats DARA Biosciences on 8 of the 9 factors compared between the two stocks.
Advanced Accelerator Application Company Profile
Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.
DARA Biosciences Company Profile
DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.
Receive News & Ratings for Advanced Accelerator Application SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Application SA and related companies with MarketBeat.com's FREE daily email newsletter.